A public offering of about 9.3 million shares of common stock has been priced by liquid biopsy test maker OncoCyte in hopes of raising about $35 million in gross proceeds. The money will be used to support the market launch of the company's blood-based assay, DetermaVu test, which is designed to differentiate between benign lung nodules and cancerous ones.
OncoCyte seeks to raise $35M in public offering
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.